Эрлотиниб
Эрлотиниб атрибут
| Температура плавления: |
159-160 °C |
| Температура кипения: |
553.6±50.0 °C(Predicted) |
| плотность: |
1.24 |
| температура хранения: |
Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| растворимость: |
Хлороформ (Мало растворим), ДМСО (Мало растворим), метанол (Мало растворим) |
| форма: |
Твердый |
| пка: |
5.32±0.30(Predicted) |
| цвет: |
белый |
| InChI: |
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) |
| ИнЧИКей: |
AAKJLRGGTJKAMG-UHFFFAOYSA-N |
| SMILES: |
N1=C2C(C=C(OCCOC)C(OCCOC)=C2)=C(NC2=CC=CC(C#C)=C2)N=C1 |
| Справочник по базе данных CAS: |
183321-74-6(CAS DataBase Reference) |
| Рейтинг продуктов питания EWG: |
1 |
| Словарь онкологических терминов NCI: |
Tarceva |
| FDA UNII: |
J4T82NDH7E |
| Словарь наркотиков NCI: |
Tarceva |
| Код УВД: |
L01EB02 |
| UNSPSC Code: |
12352200 |
| NACRES: |
NA.77 |
Эрлотиниб химические свойства, назначение, производство
Описание
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.
Использование
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.
Определение
ChEBI: A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.
Общее описание
Class: receptor tyrosine kinase
Treatment: NSCLC
Oral bioavailability = 60%
Elimination half-life = 36 h
Protein binding = 93%
Побочные эффекты
- Burning, tingling, numbness or pain in the hands, arms, feet, or legs.
- cough or hoarseness.
- diarrhea (severe)
- difficult or labored breathing.
- fever or chills.
- rash (severe)
- sensation of pins and needles.
- stabbing chest pain.
Эрлотиниб препаратная продукция и сырье
сырьё
препарат
Эрлотиниб поставщик
Global( 386)Suppliers
183321-74-6(Эрлотиниб)подобный поиск: